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Abstract 
Objectives: To systematically review the literature to examine the methods used to identify 
inappropriate prescribing of preventative medication in patients with life limiting illness and to detail 
the nature of medications prescribed.  
Methods: A systematic literature search of four databases was undertaken (Medline, Embase, 
CINAHL, PsycINFO) from inception to April 2015 to identify peer-reviewed, observational studies 
assessing inappropriate prescribing of preventative medication in patients with life limiting illness.  
Inclusion criteria were: participants had a life limiting illness; prescribed/dispensed/using preventative 
medication; medication appropriateness assessed as a specific study aim or outcome.   
Results: We found 19 studies meeting our eligibility criteria. The methods used to assess medication 
appropriateness included criteria developed for the elderly such as the Beers criteria, and STOPP 
criteria, Delphi consensus and expert clinical opinion. Lipid regulating drugs (12 studies), 
antihypertensive (11 studies) and anti-diabetic medications (9 studies) were the most common classes 
of inappropriate medication identified.  
Conclusion: Patients with life limiting illnesses are prescribed preventative medications considered 
inappropriate in the context of diminished life expectancy.  The way in which preventative medication 
appropriateness is assessed in patients with life limiting illness varies considerably – with some 
methodologies utilising criteria previously developed for elderly populations.  Given this lack of 
standardisation, improving the prescribing in this context requires an approach that is specifically 
designed and validated for populations with life limiting illness. 
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Introduction  
Polypharmacy and pill burden are common in patients with life limiting illness such as cancer, heart 
failure, renal disease and dementia.[1] A key priority for healthcare professionals, when caring for 
these patients, is balancing chronic disease management and palliation of acute symptoms. An 
important element of this process is ensuring that the benefit of any prescribing decisions outweighs 
the potential risks. This can be particularly challenging, as many co-morbidities are treated with 
chronic medications to maintain, or are prescribed to prevent further worsening of the disease state.  
Such preventative medications may not treat symptoms of the underlying disease; however, stopping 
preventative medications could, in theory, further worsen the co-morbidity, resulting in the 
exacerbation of symptoms.[2]   
 
In the context of diminished life expectancy, prescribing preventative medications may be 
inappropriate given the time until benefit can be several years and patients are at increased risk of 
developing a drug-related toxicity due to their altering pharmacokinetic and pharmacodynamic 
profiles.[3, 4]  To assist healthcare professionals in making prescribing decisions for this patient 
population, a series of frameworks have been developed to promote rational prescribing and reduce 
the use of unnecessary and potentially harmful care.[5, 6] However, despite these approaches, and the 
policy drivers advocating the use of preventative medication,[7] it is unclear to what extent 
preventative medications are prescribed for patients with life limiting illness.  Therefore, this study 
aimed to systematically review the peer-reviewed literature to examine the methods used to identify 
inappropriate prescribing of preventative medication in patients with life limiting illness and to detail 
the nature of medications prescribed. 
 
Methods 
The review was carried out and reported according to the Preferred Reporting in Systematic Reviews 
and Meta-analyses (PRISMA) guidelines;[8] the protocol was registered with PROSPERO 
CRD42014013733. 
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Data sources 
The following databases were searched to identify relevant studies: MEDLINE (Ovid), EMBASE 
(Ovid), CINAHL and PsycINFO.  All databases were searched from their respective start dates to 
April 2015; studies were limited to those reported in English.  The search strategy was modified, 
when appropriate, to suit syntax requirements (see Appendix 1); search terms were focused to title 
and abstract.  The bibliographies of all included studies were hand searched; information was also 
requested from key experts in the field relating to on-goings studies.  
 
Study selection 
To be included in the review, studies had to meet the following criteria:  
1. Population: patients with life limiting illness prescribed/dispensed/using preventative 
medication.  For the purposes of the review, life limiting illness is defined as a malignant 
or non-malignant condition that would significantly reduce life expectancy including 
cancer, advanced dementia, advanced heart failure, end-stage chronic obstructive 
pulmonary disease (COPD) or advanced Parkinson’s disease; preventative medication is 
defined as any medication used for primary, secondary or tertiary prevention to avert and 
avoid disease, including lipid regulating medication, anti-hypertensive medication, anti-
diabetic medication, antiplatelet medication.  
2. Study type: all types of observational studies including case series, cross sectional and 
cohort studies in routine care.  
3. Outcomes: assessed medication ‘appropriateness’ (included specifically as a study aim or 
outcome measure) and whether preventative medication was discontinued in included 
studies. 
 
Exclusion criteria 
We excluded the following studies: 
1. Those examining prescribing of preventative medication in populations without life limiting 
illness (e.g. elderly patients).  
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2. Those reporting prescribing/dispensing/medication use in patients with life limiting illnesses, 
without assessing medication appropriateness. 
3. Those reported as a conference abstract. 
 
Study selection and screening 
The initial screening of titles and abstracts was conducted independently by two reviewers (IA and 
LL), with a random 10% of the sample checked by a third reviewer (AT).  Full-paper study inclusion 
and data extraction was conducted independently by two reviewers (IA and LL); the following data 
was extracted from included studies: study objectives, population, setting, life limiting illness, 
methodology to assess medication appropriateness, primary outcome relating to inappropriate 
medication use, types of preventative medication (either class or individual medication), whether 
medication was discontinued as part of the study; comprehensiveness of reporting based on the 
STROBE checklist.[9]  Any discrepancies were resolved through discussion and, if agreement was 
not reached, by consensus with the project lead (AT). 
 
Data extraction quality appraisal  
In the absence of a validated quality assessment tool suitable for all observational studies, including 
case series studies, we assessed the comprehensiveness of reporting using the STROBE checklist, 
based on ten key items from the guideline (items 2, 3, 5, 6-8, 10, 14, 16, 22).[9] This was done 
independently by two reviewers (IA and LL); any discrepancies were discussed and agreement was 
reached by consensus (AT). 
 
Reporting 
Due to the heterogeneity of study methodology and outcomes, we could not use traditional meta-
analytic approaches to combine individual study results. Instead, we described key study features 
using a narrative approach across the included studies. 
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Results  
Literature search 
There were 20,343 hits generated from the initial literature search. After duplicates were removed, 
13,472 studies were screened for eligibility, based on title and abstract; from this, 88 articles were 
selected for a full text review.  After a full paper screen, 19 individual studies were included in the 
review; reasons for study exclusion were: not focused on preventative medications, not assessing 
medication appropriateness, not assessing patients with a life limiting illness, paper was a review of 
the literature, opinion piece/editorial, (Figure 1); included studies are summarised in Table 1. 
 
Please insert Table 1 around here 
 
Quality appraisal 
All studies reported on the rationale, scientific background and settings of the work, as well as 
defining the sources of data.  Two of the studies did not clearly state primary objectives,[11, 22] while 
only one provided justification of the sample size used.[17] The remaining studies recruited 
participants over a defined time period (either retro- or prospectively) or used pre-specified number of 
patients; neither approach stated a firm rationale or basis.  Basic participant demographics, such as 
gender, age and details of life limiting illness, were reported in all but one of the studies.[24] Nine of 
the studies reported a funding source.[10, 12, 14, 20, 21, 25-28] 
 
Participants 
The total number of patients included in the studies was 10,220, ranging from 20 [26] to 5405 
patients.[27] The most common life limiting illness described in the studies was cancer: nine studies 
examined medication use in different cancers,[11, 14, 15, 17, 19-23] while one study focused 
exclusively on patients with advanced lung cancer.[27] Four studies explored medication use in 
patients with dementia,[12,18, 25, 26] and two focused on patients with terminal illness in a palliative 
care environment;[24, 28] the most common condition in these studies was cancer, although patients 
with advanced heart failure, end stage COPD, and Parkinson’s disease were also included. One study 
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explored how diabetes is managed in terminally ill patients;[16] the life limiting illness of each patient 
was not stated, and the study focused exclusively on anti-diabetic medication. The remaining studies 
included patients with advanced heart failure [10] and chronic kidney disease.[13] 
 
Settings 
Nine were based in hospitals,[10, 11, 13, 15, 16-18, 22, 27] three within palliative care settings,[14, 
24, 28] three within outpatient oncology clinics,[19, 20, 23] one within a long-term care facility,[12] 
two within nursing homes,[25, 26] and one study compared medication use for patients attending a 
hospice and hospital.[21] 
 
Criteria to assess medication appropriateness 
The methodology used to assess medication appropriateness was wide ranging.  Several studies used 
previously developed methodology to aid prescribing decisions in older people;[10, 13, 19, 20, 23, 
24] these included the Screening Tool of Older Persons’ potentially inappropriate Prescriptions 
(STOPP) criteria,[29] the Beers criteria [30] and the Unnecessary Drug Use Measure (which contains 
three items from the Medication Appropriateness Index [31]). In contrast to these approaches, 
Lindsay and colleagues, using the current literature as an evidence base, developed and validated their 
own guideline, the Onc-Pal deprescribing guideline, to assess medication appropriateness.[17] 
 
Other studies utilised the opinion of the clinical experts to assess medication appropriateness: Fede 
and colleagues used this approach to develop a set of explicit criteria (e.g. using a statin when there 
was a lack of any cardiovascular event in the prior 12 months was considered inappropriate) to 
determine if a medication was considered ‘futile’,[11] while Rajimakers surveyed international 
experts to gather opinion on medication appropriateness and subsequently applied this to assess 
prescribing in a cohort of cancer patients.[21] Riechelmann also assessed medication futility but 
defined it as when there were no short-term benefit to patients with respect to survival, quality of life, 
or symptom control.[22]  The methodologies developed by Fede and Riechelmann to assess 
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medication futility were also deployed by Kotlinska-Lemieszek [14] and Lee,[15] who assessed 
prescribing in cohorts of patients with terminal cancer.  
 
Todd and colleagues assessed medication appropriateness by surveying the clinical team [27] or 
through a Dephi consensus of pharmacists and palliative care consultants;[28] both approaches used a 
conceptual framework to guide decision making that considered: remaining life expectancy; time until 
benefit; goals of care and treatment targets.[5]  Similarly, Holmes and colleagues [12] also employed 
a Delphi process of 12 geriatricians to determine if the medication was: always appropriate, 
sometimes appropriate, rarely appropriate and never appropriate; the results from this study in terms 
of what constituents an inappropriate medication were applied to the work of Tjia [25, 26] who 
explored medication use in nursing residents with advanced dementia. 
 
Types of inappropriate medication 
The most common preventative class of medication assessed to be inappropriate were the lipid 
lowering agents – the most common of which were the statins; this was reported in the majority of 
studies.[11-15, 17, 18, 22, 25-28] Other classes of inappropriate medication identified included 
vitamins and mineral supplements,[11, 14, 18, 20, 22, 24, 28] antidiabetic,[10, 11, 13, 15-19, 24] 
antihypertensive,[10, 11, 13-15, 17-19, 21, 23, 28] antiplatelet [10, 12, 17-19, 26-28] and antiulcer 
medication.[14, 17, 19, 21, 27] 
 
Discussion 
The review identified a number of studies demonstrating that preventative medications are prescribed 
inappropriately to patients with various life limiting illnesses.  The class of medication most 
commonly identified as inappropriate or ‘futile’ were the lipid lowering agents – with statins being 
the most frequent.  This finding is supported by several cohort studies that show statins continue to be 
prescribed in patients with diminished life expectancy,[32, 33] while it is also acknowledged that 
being diagnosed with a life limiting illness does not decrease statin use in that patient subgroup.[34]  
The use of statins in life limiting illness has also been acknowledged by the Choosing Wisely 
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initiative who recommend to avoid the routine use of lipid-lowering medications in patients with 
limited life expectancy.[35]  Our review demonstrates that lipid-lowering medications are being 
prescribed to patients within this context, but it is too early to ascertain if this policy recommendation 
has changed prescribing behaviour in practice.  This observation is also timely considering the policy 
shift across the world to lower the threshold criteria to initiate statin therapy, which will significantly 
increase the number of patients taking a statin for primary prevention.[36, 37]  
 
Our review demonstrated a range of methodologies assessing medication appropriateness; several 
studies used expert opinion or based the decisions on the literature, while others utilised methodology 
originally developed to aid prescribing decisions in older people.  Lipid-lowering agents were the 
class of preventative medications most commonly identified as inappropriate in our review yet studies 
that used the STOPP criteria, Beers criteria or Unnecessary Drug Use Measure did not assess lipid-
lowering medication as inappropriate, as this class of drugs are not part of these instruments. Indeed, 
as many of these instruments were originally designed to assess medication appropriateness in an 
elderly population, the utility in patients’ with life limiting illness may be inadequate and, in some 
cases, counter intuitive.  Given this lack of standardisation, improving the prescribing in this context 
requires an approach that is specifically designed and validated for populations with life limiting 
illness.   More support – possibly in the form of clear practical guidelines – should be made available 
to all healthcare professionals with responsibility for prescribing medication to patients with life 
limiting illness. 
 
In recent years, the term ‘deprescribing’ – a way of rationalising medication that provides a limited 
benefit to patients – has been introduced to the world of pharmaceutical care.  A timely article by 
Scott and colleagues, presenting a simple 5-step protocol to support deprescribing, define it as the 
systematic process of identifying and discontinuing drugs in instances in which existing or potential 
harms outweigh existing or potential benefits within the context of an individuals patient’s care goals, 
current level of functioning, life expectancy, values and preferences.[38].  Indeed, our work in the 
context of life limiting illness, supports the concept of deprescribing and demonstrates that it should 
 10 
be incorporated into all aspects of the prescribing process; many guidelines only state when to start a 
medication, but seldom explained when and how to discontinue or deprescribe a medication.  From 
the studies identified in our review, only one, by Brunet and colleagues [18], actively discontinued or 
deprescribed inappropriate preventative medication.  For this study, over 60 per cent of preventative 
medication was stopped due to a lack of an evidence base, with the majority of medication indicated 
for primary prevention.  Unfortunately, this study did not ascertain how stopping preventative 
medication affected patients long-term.  
 
There is a dearth of literature exploring how deprescribing preventative medication amongst patients 
with life limiting illness affects patient outcomes.  Garfinkel has shown that stopping medication in a 
frail elderly population can be associated with improved quality of living and reduced mortality 
rates.[39]  At present, it is not clear if these benefits are directly transferable to stopping medication in 
patients with life limiting illnesses.  Of note, a recent randomised trial on statin discontinuation in 
patients with anticipated life expectancy from one month to one year, showed the rate of death was 
similar between the two groups, while the group that discontinued the statins had a longer median 
time-to-death (229 days compared to 190 days).[40]  The trial also showed that the patients who 
discontinued the statins had a better quality of life, compared to those that continued statin therapy. 
This is significant progress, but given our work shows that antihypertensive and anti-diabetic 
medications are also frequently – and perhaps inappropriately – prescribed to patients with life 
limiting illness, it would be prudent to focus future trials on these medications to establish evidence-
based approaches to deprescribing medication. 
 
Another aspect of deprescribing also warranting further exploration is how patients perceive 
medication discontinuation when they have a life limiting illness.  This is clearly a complex area, but 
it is conceivable that when a patient is diagnosed with a life limiting illness, they may view the value 
and benefit of preventative medication differently, in a light of a change in life expectancy.  This may 
also be true for healthcare professionals who are involved in the prescribing decisions of those 
patients.  A study investigating decision-making associated with prescribing in elderly patients 
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showed that GPs perceive discontinuing preventative medication as more challenging when compared 
to discontinuing medication indicated to treat acute conditions.[41]  While Sand et al, who explored 
medication use in a group of patients with advanced cancer, showed there was a desire to reduce the 
number of tablets they take, as the medication reminded them of their illness.[42]  A qualitative study 
building on these findings exploring preventative medication discontinuation in life limiting illness 
from the viewpoint of prescribers and patients would therefore be valuable. 
 
There have been several reviews undertaken to identify inappropriate prescribing in patients with 
diminished life expectancy, although none have systematically reviewed the literature to examine the 
methods used to identify inappropriate prescribing of preventative medication in patients with life 
limiting illness.  The most recent, a review by Lindsay et al [43], focused exclusively on cancer 
patients and concluded that there is evidence that potentially inappropriate medications (PIMs) are 
commonly prescribed in cancer patients.  A recent review by Tjia and colleagues [44], who focussed 
on intervention studies that reduced unnecessary medication in frail elderly patients, concluded that 
there has was a lack of robust high quality evidence in this area and more work was needed to inform 
evidence based approaches to deprescribing medication.  Our work, which is the first to 
systematically review the literature in relation to inappropriate preventative medication use in life 
limiting illness, builds on these findings and shows many patients in this context – not just those with 
cancer, as identified by Lindsay et al – continue to take preventative medication inappropriately.   
 
While we believe our results are robust and have important implications for prescribing preventative 
medication to patients with life limiting illness, we acknowledge that our work has limitations.  
Firstly, the definition we used for preventative medication is broad.  It is possible that some 
medications we considered preventative included in the review also have an affect on the control of 
acute symptoms (e.g. treating hyperglycaemia with an antidiabetic medication may relieve symptoms 
associated with fatigue as well as preventing long term complications), which may be beneficial to the 
patient.  Secondly, as with all reviews, this systematic review may be subject to publication bias: it is 
possible that observational studies that did not show inappropriate prescribing in patients with life 
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limiting illness have a lower chance of being published, meaning that we have over-estimated the 
extent of inappropriate prescribing.  We acknowledge these factors as limitations of our work; the 
results of this review should be interpreted with this in mind. 
 
Conclusion 
Patients with life limiting illnesses are commonly prescribed preventative medications that are 
considered inappropriate in the context of diminished life expectancy.  The way in which preventative 
medication appropriateness is assessed in patients with life limiting illness varies considerably – with 
some methodologies utilising criteria that were previously developed for elderly populations.  Given 
the lack of standardisation, improving the prescribing for patients with life limiting illness requires a 
new approach.  Consideration should therefore be given to incorporating deprescribing approaches 
into clear practical treatment guidelines. 
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Author Objective Setting Population Methods used to 
assess 
appropriateness 
Study Outcome Examples of preventative 
medication considered 
inappropriate 
Discontinued 
as part of the 
study 
 
Quality 
score  
Barcelo 
(2014) 
Spain [10] 
Analysed the appropriateness of 
medication prescribed to patients with 
heart failure with an estimated median 
survival time of less than 6 months 
 
 
Geriatric 
ward 
Advanced 
heart 
failure 
 
n=72 
STOPP criteria 20 medications 
considered 
inappropriate 
Calcium channel blockers, 
clopidogrel, alpha blockers, 
aspirin, chlorpropamide, 
No 7 
Fede (2011) 
Brazil [11] 
Identified medications that were 
considered unnecessary as defined by 
explicit criteria that considered 
whether drugs could benefit patients 
with terminal cancer 
 
 
Hospital Advanced 
cancer 
 
n=87 
Explicit criteria 
developed by 
the literature 
and expert 
opinion (2 
oncologists and 
palliative care 
physician) 
 
21 patients using 
inappropriate 
medication  
Metformin, calcium 
supplements, captopril, 
vitamin B, statins 
 
No 6 
Holmes 
(2008) USA 
[12] 
Evaluated the feasibility of 
developing consensus 
recommendations for appropriate 
prescribing for patients with advanced 
dementia.  From this, the frequency of 
inappropriate prescribing was 
determined in a cohort of patients 
with advanced dementia 
 
 
Long-term 
care 
facilities 
Advanced 
dementia 
 
n=34 
Expert 
consensus panel 
through Delphi 
technique 
(12 
geriatricians) 
10 patients using 
inappropriate 
medication  
 
Clopidogrel, statins No 7 
Jones 
(2013) 
UK 
[13] 
Examined the prevalence of 
potentially inappropriate medication 
in elderly patients with chronic 
kidney disease 
 
 
Hospital Chronic 
kidney 
disease 
(stages 3-5; 
average 
eGFR 17.2 
mL/min) 
 
n=100 
 
Beers criteria 
and BNF 
guidance for 
prescribing in 
patients with 
renal 
impairment 
56 patients were 
prescribed one or 
more potentially 
inappropriate 
medication 
Antihypertensive agents, 
antidiabetic agents, lipid 
lowering agents  
No 6 
Kotlinska-
Lemieszek 
Analysed medication use and 
identified unneeded drugs among a 
Palliative 
care and 
Cancer 
 
When the 
medications are 
Approximately 45% 
of patients used at 
Lipid-lowering drugs, 
vitamins, minerals, 
No 6 
 14 
(2014) 
Europe 
[14] 
cohort of patients with advanced 
cancer and pain who were using Step 
III opioids 
cancer 
centres 
n=2282 
 
not thought to 
have beneficial 
effect on 
symptom 
control, quality 
of life or 
survival (from 
[11, 22]) 
 
least one drug 
categorised as 
unnecessary or 
potentially 
unnecessary  
cardiovascular agents, 
gastroprotective agents 
Lee (2013) 
Korea [15] 
Evaluated the prescribing of 
medication as essential or futile in 
terminal cancer patients 
Haemato-
oncology 
department 
within a 
hospital 
setting 
 
Terminal 
cancer 
(progressed 
advanced 
cancer with 
life 
expectancy 
of less than 
6 months) 
 
n=196 
 
When the 
medications are 
not thought to 
have beneficial 
effect on 
symptom 
control, quality 
of life or 
survival (from 
[11, 22]) 
87 medications 
considered 
inappropriate  
 
Anti-hypertensives, anti-
diabetics, statins 
 
No 6 
Lim (2009) 
UK [16] 
Established how diabetes is monitored 
and managed in terminally-ill diabetic 
patients  
Hospital Terminally 
ill patients 
with type 2 
diabetes 
 
n=25 
 
Standards based 
on the literature 
2 patients using 
inappropriate 
medication 
Oral hypoglycaemic 
medication and insulin 
No 7 
Lindsay 
(2014) 
Australia 
[17] 
Designed and validated a 
deprescribing guideline for palliative 
cancer patients; a descriptive analysis 
was undertaken to identify potentially 
inappropriate medication 
Hospital 
 
 
Cancer 
(progressed 
advanced 
cancer with 
life 
expectancy 
of less than 
6 months) 
 
n=61 
 
OncPal 
describing 
Guideline 
developed by 
the authors 
(compared to an 
expert panel as 
a way of 
validation) 
43 patients using 
inappropriate 
medication 
Aspirin, anticoagulants, 
anti-hypertensives,  
dyslipidaemic agents, oral 
hypoglycaemics, agents 
used for peptic ulcer 
prophylaxis 
 
 
No 8 
Molist 
Brunet 
(2013) 
Spain [18] 
Described the re-orientation of drug 
therapy using a patient centred 
approach with a multidisciplinary 
team to review medication; review 
Acute 
geriatric 
unit 
 
Advanced 
Dementia 
 
n=73 
Multidisciplinar
y team (2 
geriatricians and 
pharmacist) 
Number of 
inappropriate 
medications not 
stated 
Antiplatlets, 
antihypertensives, 
hypolypidemics, 
anticoagulants, 
Yes 6 
 15 
established new therapeutic objectives 
based on end-of-life care 
 with the 
patient/carer 
(3 point patient 
centred 
medication 
therapy plan) 
antidiabetics, nutritional 
supplements 
Nightingale 
(2015) 
USA 
[19] 
Retrospectively examined medication 
use in ambulatory senior adults with 
cancer to determine prevalence of 
polypharmacy and potentially 
inappropriate medication use 
Outpatient 
oncology 
clinic 
Cancer 
 
n=234 
Beers criteria 
STOPP 
HEDIS 
94 patients using a 
potentially 
inappropriate 
medication (Beers) 
 
88 patients using a 
potentially 
inappropriate 
medication 
(STOPP) 
 
49 patients using a 
potentially 
inappropriate 
medication (HEDIS 
criteria) 
 
Antiplatelet, long-acting 
sulfonylureas, sliding scale 
insulin, hydrochlorothiazide 
No 6 
Prithviraj 
(2012) 
USA 
[20] 
Identified patient characteristics 
associated with polypharmacy and 
inappropriate medication use among 
older patients with a recent cancer 
diagnosis 
 
 
Oncology 
clinic 
Cancer 
 
n=117 
Beers criteria The prevalence of 
potentially 
inappropriate 
medication use was 
44% 
Iron supplements, digoxin No 9 
Raijmakers 
(2013) Italy 
[21] 
Described medication use and 
assessed for potentially in terminally 
ill cancer patients and  
Hospital and 
hospice 
 
 
Cancer 
 
n=195 
List generated 
through a 
survey with 
international 
experts 
 
327 medications 
considered 
inappropriate 
Anticoagulants, 
antihypertensives, antiulcer 
drugs 
 
 
No 7 
Riechelman
n (2009) 
Canada [22] 
Assessed futile (when no short-term 
benefit with respect to survival, 
quality of life, or symptom control 
was anticipated) medication use in 
Palliative 
care clinic 
within a 
hospital 
Advanced 
cancer 
 
n=372 
Medication 
profile was 
reviewed by 
researchers 
82 patients using 
inappropriate 
medication 
Statins, multivitamins, 
allopurinol, folic acid, 
ferrous gluconate, 
fenofibrate 
No 5 
 16 
terminally ill cancer patients setting 
 
 
 
Saarelainen 
(2014) 
Australia 
[23] 
Investigated the prevalence and 
factors associated with the use of 
potentially inappropriate medication 
in patients presenting to an oncology 
clinic 
 
Oncology 
outpatient 
clinic 
Cancer 
 
n=385 
 
Beers criteria 102 patients using at 
least one potentially 
inappropriate 
medication 
Prazosin No 8 
Suhri (2009) 
USA [24] 
Evaluated if a geriatric palliative care 
team reduced unnecessary medication 
prescribing for elderly veterans with a 
life limiting illness 
 
 
Geriatric 
palliative 
care unit 
 
Terminal 
illness 
(dementia, 
cancer, 
heart 
failure) 
 
n=89 
Unnecessary 
Drug Use 
Measure, which 
contains 3 items 
from the 
Medication 
Appropriateness 
Index 
 
104 medications 
considered 
inappropriate 
 
 
Vitamins, antithrombotic 
agents, endocrine agents 
No 6 
Tjia (2010) 
USA [25] 
Examined medication use in patients 
with advanced dementia; study also 
assessed medications that were “never 
appropriate” in advanced dementia 
 
 
Nursing 
homes 
 
Advanced 
dementia 
 
n=323 
Uses 
classification 
system from 
Holmes et al 
[12] 
 121 patients using 
inappropriate 
medication 
Lipid lowering agents 
 
No 9 
Tjia (2014) 
USA [26] 
Estimated the prevalence of 
medications with questionable benefit 
in nursing home residents with 
advanced dementia 
Nursing 
homes 
Advanced 
dementia  
 
n=5406 
Uses criteria 
from Holmes et 
al [12] 
2911 patients 
received at least one 
medication with 
questionable benefit 
Lipid lowering agents, 
antiplatelet agents 
(excluding aspirin) 
No 9 
Todd (2013) 
UK [27] 
Assessed the prevalence of 
inappropriate medication in lung 
cancer patients taking erlotinib 
 
 
Hospital 
 
Advanced 
lung cancer 
 
n=20 
Clinical team 
(oncologist, 
pharmacist and 
nurse) using 
Holmes et al 
framework [5] 
 
19 patients using 
inappropriate 
medication 
Proton pump inhibitors, 
aspirin, clopidogrel, statins 
No 6 
Todd (2014) 
UK [28] 
Assessed the prevalence of 
inappropriate medication use in a 
hospice population; potential drug-
drug interactions were also identified 
and it was ascertained how many 
could be prevented by discontinuing 
Tertiary 
palliative 
care centre 
Terminal 
illness 
(cancer, 
end-stage 
COPD, 
heart 
Modified 
Delphi 
consensus using 
Holmes et al 
framework [5] 
 92 patients using 
inappropriate 
medication 
Statins, vitamin and mineral 
supplements, aspirin (for 
antiplatelet therapy), 
clopidogrel, ACE inhibitors, 
fenofibrate, calcium 
channel blockers, ezetimbe, 
No 8 
 17 
 
 
inappropriate medication. 
 
 
failure, 
Parkinson’s 
disease) 
 
n=132 
 
angiotensin II receptor 
antagonists 
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Appendix 1: An example search strategy used for the Medline (Ovid) platform. 
1. Inappropriate med* 
2. Discontinu* med* 
3. Unnecessary med* 
4. Inappropriate prescribing 
5. Deprescrib* 
6. Med* optimi$ation 
7. Med* rationali$ation 
8. Med* futil* 
9. Non-essential med* 
10. Polypharmacy 
11. Statin 
12. Antihypertens* 
13. Bisphosphonate 
14. Vitamins  
15. Minerals 
16. Antiplatelet 
17. Combine 1-16 
18. Limited life expectancy 
19. Diminished life expectancy 
20. Poor prognosis 
21. Palliative 
22. Life limiting illness 
23. End of life 
 19 
24. Terminal* 
25. Advanced 
26. Oncology 
27. Cancer 
28. Chronic kidney disease 
29. End stage renal failure 
30. Chronic COPD 
31. End stage COPD 
32. Advanced dementia 
33. Advanced heart failure 
34. Combine 18-33 
35. Combine 17 and 34. 
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